{
  "label": "q_cs03_q22_counterfactual",
  "artifact_type": "question",
  "artifact_id": "sha256:a84641de5b9ea57e1243a5bdd7b7aba57a53e54b5219f1cb04438aac33d7ffb8",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:044266001cadd958fbee4c3c26f47dd870c06eeeaffdc51d0bcca59d174fce62",
    "sha256:526bf0877b15ba594954d8544c6493f2535bc8acb2239824a0eeeb941d801b2d"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:44.860077",
  "content": "{\n  \"question_id\": \"cs03_q22_counterfactual\",\n  \"scope_id\": \"clinical_signal_03\",\n  \"checkpoint_after\": 20,\n  \"question_type\": \"counterfactual\",\n  \"prompt\": \"If the ALT elevations were caused by a viral hepatitis outbreak among trial subjects, what pattern would you expect? Does the data match?\",\n  \"ground_truth\": {\n    \"canonical_answer\": \"Viral hepatitis would show clustered onset at specific sites, associated symptoms (fatigue, jaundice), and positive viral serologies. Instead, the elevations are distributed across sites and correlate with statin co-administration, not geography or viral exposure. The pattern is consistent with a pharmacokinetic interaction, not infection.\",\n    \"required_evidence_refs\": [\n      \"clinical_signal_03_ep_018\",\n      \"clinical_signal_03_ep_019\"\n    ],\n    \"key_facts\": [\n      \"multi-site signal distribution rules out site-specific confounders as causal explanation\",\n      \"the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity\",\n      \"ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event\",\n      \"the adverse signal is hepatic (ALT/AST elevation), not renal \\u2014 kidney function markers remain stable while liver enzymes diverge\",\n      \"the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns\",\n      \"Site 07 lab equipment issue is not the cause of ALT elevations\",\n      \"musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver\",\n      \"ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases\"\n    ]\n  }\n}",
  "metadata": {
    "question_id": "cs03_q22_counterfactual",
    "question_type": "counterfactual",
    "checkpoint_after": 20,
    "scope_id": "clinical_signal_03",
    "layer_name": "questions",
    "layer_level": 3,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "b7455246ea931d9aa2f027b4e8aa323652ff1f27438164e6410b2d13c35393cf",
      "components": {
        "transform": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
        "inputs": "341be996836d7673"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a7d463dc476b419c96a5f454f481b455ca81a8d8ee3904631b7729963317406f",
      "components": {
        "transform_id": "3176c030aaa3a69e",
        "source": "929fe273ac2dab06",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}